---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-049937"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2026-07-28T12:35:19+00:00"
generated_at: "2026-07-28T12:40:09.326097+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bicara Therapeutics appoints Jeremy Bender and Christy Oliger to board; Kiran Mazumdar-Shaw retires

## Summary
- Kiran Mazumdar-Shaw resigned from board effective July 28, 2026; no disagreement with company.
- Jeremy Bender (former CEO, Day One Biopharmaceuticals) and Christy Oliger (former SVP, Genentech) appointed to board effective July 28, 2026.
- Board size increased from nine to ten directors; Bender and Oliger each receive initial option award of 38,950 shares.
- New Launch Readiness Committee formed with Kate Haviland as chair, Bender and Oliger as members.
- Appointments support Bicara's transition to commercial-stage focus on ficerafusp alfa.

## SEC filing metadata
- accession: 0001628280-26-049937
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2026-07-28T12:35:19+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000162828026049937/0001628280-26-049937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000162828026049937/bcax-20260723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-049937
- JSON: https://secwatch.observer/filing/0001628280-26-049937.json
- Plain text: https://secwatch.observer/filing/0001628280-26-049937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.